SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Marinucci Silvia)
 

Search: WFRF:(Marinucci Silvia) > Higher free d-aspar...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia

Errico, Francesco (author)
Bonito-Oliva, Alessandra (author)
Bagetta, Vincenza (author)
show more...
Vitucci, Daniela (author)
Romano, Rosaria (author)
Zianni, Elisa (author)
Napolitano, Francesco (author)
Marinucci, Silvia (author)
Di Luca, Monica (author)
Calabresi, Paolo (author)
Fisone, Gilberto (author)
Karolinska Institutet
Carta, Manolo (author)
Lund University,Lunds universitet,Neurobiologi,Forskargrupper vid Lunds universitet,Neurobiology,Lund University Research Groups
Picconi, Barbara (author)
Gardoni, Fabrizio (author)
Usiello, Alessandro (author)
show less...
 (creator_code:org_t)
Elsevier BV, 2011
2011
English.
In: Experimental Neurology. - : Elsevier BV. - 0014-4886 .- 1090-2430. ; 232:2, s. 240-250
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • In Parkinson's disease (PD) progressive alteration of striatal N-methyl-D-aspartate receptors (NMDARs) signaling has emerged as a considerable factor for the onset of the adverse motor effects of long-term levodopa (L-DOPA) treatment. In this regard, the NMDAR channel blocker amantadine is so far the only drug available for clinical use that attenuates L-DOPA-induced dyskinesia (LID). In this study, we examined the influence of a basal corticostriatal hyper-glutamatergic transmission in the appearance of dyskinesia, using a genetic mouse model lacking D-Aspartate Oxidase (DDO) enzyme (Ddo(-/-)mice). We found that, in Ddo(-/-)mice, non-physiological, high levels of the endogenous free D-amino acids D-aspartate (D-Asp) and NMDA, known to stimulate NMDAR transmission, resulted in the loss of corticostriatal synaptic depotentiation and precocious expression of LID. Interestingly, the block of depotentiation precedes any change in dopaminergic transmission associated to 6-OHDA lesion and L-DOPA treatment. Indeed, lesioned mutant mice display physiological L-DOPA-dependent enhancement of striatal D1 receptor/PKA/protein phosphatase-1 and ERK signaling. Moreover, in line with synaptic rearrangements of NMDAR subunits occurring in dyskinetic animal models, a short L-DOPA treatment produces a dramatic and selective reduction of the NR2B subunit in the striatal post-synaptic fraction of Ddo(-/-) lesioned mutants but not in controls. These data indicate that a preexisting hyper-glutamatergic tone at NMDARs in Ddo(-/-) mice produce abnormal striatal synaptic changes that, in turn, facilitate the onset of LID. (C) 2011 Elsevier Inc. All rights reserved.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Keyword

D-amino acids
NMDA receptor
L-DOPA
Dyskinesia

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view